Efficacy and Safety of Fractional 1064-nm Picosecond Laser for Facial Skin Tightening

Mahidol University

Status

Enrolling

Conditions

Laxity; Skin

Treatments

Device: StarWalker® PQX

Study type

Interventional

Funder types

Other

Identifiers

NCT06231914

Si 981/2023

Details and patient eligibility

About

The goal of this clinical trial is to learn the efficacy and safety of fractional 1064-nm picosecond laser for facial skin tightening. The main questions it aims to answer are:

Efficacy of fractional 1064-nm picosecond laser for facial skin efficacy including the changes in wrinkle, nasolabial fold, skin laxity, and skin elasticity
The changes in texture and pore volume using Antera
The changes in bioengineering assessment: melanin index, erythema index, sebum level
Adverse events Participants will be treated with 3 sessions of fractional 1064-nm picosecond laser (full face 4 passes, vector lines 4 passes), spaced 4 weeks apart. Follow-up visits 1, 3, and 6 months after the last treatments.

Full description

The efficacy and safety of fractional 1064-nm picosecond laser for facial skin tightening in participants aged 40 to 55 years, BMI < 25 kg/m2, and have mild to moderate facial laxity.

Enrollment

30 estimated patients

Sex

All

Ages

40 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Aged 40-55 years
BMI < 25 kg/m2
Asian
Mild to moderate facial skin laxity using quantitative grading scale (grade 1.5-2.5)

Exclusion criteria

Pregnant or lactation
Subjects who have been treated with any kind of energy-based device 6 months prior to the inclusion
Subjects who have been injected with botulinum toxin, filler, or platelet-rich plasma on their faces 6 months prior to the inclusion
Active skin infections
History of hypertrophic scars or keloids